New oral anticoagulant agents – general features and outcomes in subsets of patients

A specific antidote for dabigatran: functional and structural characterization

(2013) F. Schiele et al.   BLOOD

Activated prothrombin complex concentrate for dabigatran-associated bleeding

(2013) Sam Schulman et al.   BRITISH JOURNAL OF HAEMATOLOGY

Management and Outcomes of Major Bleeding During Treatment With Dabigatran or Warfarin

(2013) Ammar Majeed et al.   CIRCULATION

Reversing Dabigatran in Life-Threatening Bleeding Occurring During Cardiac Ablation With Factor Eight Inhibitor Bypassing Activity

(2013) William E. Dager et al.   CRITICAL CARE MEDICINE

Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060

(2013) B. P. Krijthe et al.   EUROPEAN HEART JOURNAL

Stroke prevention in atrial fibrillation—An Asian stroke perspective

(2013) Hung-Fat Tse et al.   HEART RHYTHM

Efficacy and Safety of Dabigatran Etexilate and Warfarin in “Real-World” Patients With Atrial Fibrillation

(2013) Torben Bjerregaard Larsen et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa

(2013) Genmin Lu et al.   NATURE MEDICINE

Dabigatran versus Warfarin in Patients with Mechanical Heart Valves

(2013) John W. Eikelboom et al.   NEW ENGLAND JOURNAL OF MEDICINE

Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism

(2013)   NEW ENGLAND JOURNAL OF MEDICINE

Edoxaban versus Warfarin in Patients with Atrial Fibrillation

(2013) Robert P. Giugliano et al.   NEW ENGLAND JOURNAL OF MEDICINE

Extended Use of Dabigatran, Warfarin, or Placebo in Venous Thromboembolism

(2013) Sam Schulman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Oral Apixaban for the Treatment of Acute Venous Thromboembolism

(2013) Giancarlo Agnelli et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dabigatran Versus Warfarin

(2013) Masatsugu Hori et al.   STROKE

Do open label blinded outcome studies of novel anticoagulants versus warfarin have equivalent validity to those carried out under double-blind conditions?

(2013) William O’Neil et al.   THROMBOSIS AND HAEMOSTASIS

Effective elimination of dabigatran by haemodialysis

(2013) Stephan Formella et al.   THROMBOSIS AND HAEMOSTASIS

Dabigatran Association With Higher Risk of Acute Coronary Events

(2012) Ken Uchino   ARCHIVES OF INTERNAL MEDICINE

The Global Burden of Atrial Fibrillation and Stroke

(2012) Gregory Y.H. Lip et al.   CHEST

Myocardial Ischemic Events in Patients With Atrial Fibrillation Treated With Dabigatran or Warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) Trial

(2012) Stefan H. Hohnloser et al.   CIRCULATION

Periprocedural Bleeding and Thromboembolic Events With Dabigatran Compared With Warfarin

(2012) Jeff S. Healey et al.   CIRCULATION

Concomitant Use of Antiplatelet Therapy with Dabigatran or Warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Trial

(2012) Antonio L. Dans et al.   CIRCULATION

Female sex as a risk factor for stroke in atrial fibrillation: a nationwide cohort study

(2012) A. P. MIKKELSEN et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism

(2012)   NEW ENGLAND JOURNAL OF MEDICINE

Apixaban for Extended Treatment of Venous Thromboembolism

(2012) Giancarlo Agnelli et al.   NEW ENGLAND JOURNAL OF MEDICINE

The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0–1: A nationwide cohort study

(2012) Christian Torp-Pedersen et al.   THROMBOSIS AND HAEMOSTASIS

Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation

(2011) John W. Eikelboom et al.   CIRCULATION

Apixaban versus Warfarin in Patients with Atrial Fibrillation

(2011) Christopher B. Granger et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation

(2011) Manesh R. Patel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a ‘real world’ atrial fibrillation population: A modelling analysis based on a nationwide cohort study

(2011) Amitava Banerjee et al.   THROMBOSIS AND HAEMOSTASIS

Prevalence of clinical venous thromboembolism in the USA: Current trends and future projections

(2010) S. B. Deitelzweig et al.   AMERICAN JOURNAL OF HEMATOLOGY

Influence of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Oral Dabigatran Etexilate

(2010) Joachim Stangier et al.   CLINICAL PHARMACOKINETICS

Cardiostim Editorial

(2010) A. J. Camm   EUROPACE

Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial

(2010) Lars Wallentin et al.   LANCET

Oral Rivaroxaban for Symptomatic Venous Thromboembolism

(2010)   NEW ENGLAND JOURNAL OF MEDICINE

Dabigatran etexilate – a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity

(2010) Joachim Stangier et al.   THROMBOSIS AND HAEMOSTASIS

Metabolism and Excretion of Rivaroxaban, an Oral, Direct Factor Xa Inhibitor, in Rats, Dogs, and Humans

(2009) C. Weinz et al.   DRUG METABOLISM AND DISPOSITION

Dabigatran versus Warfarin in Patients with Atrial Fibrillation

(2009) Stuart J. Connolly et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism

(2009) Sam Schulman et al.   NEW ENGLAND JOURNAL OF MEDICINE